Accumulated CV data from SGLT2i outcomes trials

Summary of clinical and scientific topics discussed at EASD 2020 congress

Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology

Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial

Highlights of the 2019 EASD Congress

DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial

Early intervention with oral semaglutide and long term safety

VERIFY and CONCLUDE study

Cardio-renal risk

Clinical properties and differences between GLP-1 agonists

Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes

Diabetic retinopathy: Is the eye a mirror of the brain?

Cardiovascular mode of action of GLP-1 receptor agonists

Exploring the effects of SGLT2 inhibition in ongoing clinical trials

Cardiovascular outcome trials: putting recent updates into perspective

Clinical insights into recent EXAMINE trial data: an evolving story

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

50 years of clinical research in diabetes

50 years in treatment of diabetes complications

50 years of diabetes treatment

75 years with diabetes – a patient’s perspective